Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. A replay of the webcast will be available in the Investors section of the company’s website following the event. To view the full press release, visit https://ibn.fm/A9CfR.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The upcoming earnings call is important for investors as it will provide updates on the commercial launch of TONMYA and progress of clinical trials. The company’s ability to capitalize on the fibromyalgia market and advance its pipeline candidates will be key topics. For the latest news and updates relating to TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.
